IGF-1 LR3 vs Des(1-3)IGF-1: Truncation, IGF-Binding Protein (IGFBP) Resistance, and Myogenic Potency
A comparative molecular analysis between IGF-1 LR3 and Des(1-3)IGF-1. Structural modifications, IGFBP-3 binding kinetics, receptor affinity, and satellite cell proliferation assays. Native IGF-1 is rapidly sequestered by IGF-binding proteins (IGFBPs), limiting free bioavailable peptide to less than 1%.
- Native IGF-1 is rapidly sequestered by IGF-binding proteins (IGFBPs), limiting free bioavailable peptide to less than 1%.
- IGF-1 LR3 contains an N-terminal 13-amino-acid extension (MFPAMPLLSLFV) and an Arg3 substitution, reducing IGFBP affinity by >100-fold and extending half-life to 20–30 hours.
- Des(1-3)IGF-1 lacks the first three N-terminal residues (Gly-Pro-Glu), increasing local receptor potency by 10-fold with a short 20–30 minute half-life.
- Both recombinant analogs activate the IGF-1R tyrosine kinase, stimulating downstream PI3K/Akt/mTORC1 and MAPK cascades.
| CAS Registry Number | 946870-92-4 |
|---|---|
| Molecular Formula | C400H625N111O115S9 |
| Molecular Mass | 9117.5 g/mol |
| Primary Biological Target | Type 1 Insulin-like Growth Factor Receptor (IGF-1R) & PI3K/Akt/mTOR |
| Analytical Purity Standard | ≥99.0% (RP-HPLC, C18, 214/220 nm) |
| Identity Verification | ESI-MS (±0.1 Da) + Karl Fischer Moisture (<3.0%) |
| Lyophilized Storage | -20°C desiccated, protected from UV light (24–36 months) |
| Reconstituted Storage | 2°C–8°C refrigerated (up to 28 days in 0.9% BA BAC water) |
1. Molecular Modifications: Long R3 vs Truncated Des(1-3)
Recombinant Human IGF-1 is a 70-amino-acid polypeptide. In biological systems, more than 99% of circulating IGF-1 is bound in a high-affinity ternary complex with IGFBP-3 and the acid-labile subunit (ALS). To investigate unconstrained IGF-1 signaling, two distinct analogues were developed: (1) Long R3 IGF-1 (IGF-1 LR3, 83 amino acids), which features a 13-residue N-terminal peptide extension and a substitution of Glutamic Acid at position 3 with Arginine (Glu3Arg); (2) Des(1-3)IGF-1 (67 amino acids), a naturally occurring truncated variant lacking the first three residues (Gly-Pro-Glu) at the N-terminus.
2. IGFBP Binding Inactivation and Receptor Affinity
Surface plasmon resonance (SPR) measurements reveal that both the Glu3Arg substitution in IGF-1 LR3 and the deletion of the Gly-Pro-Glu tripeptide in Des(1-3)IGF-1 eliminate the electrostatic interaction with IGF-binding proteins (IGFBP-1 through IGFBP-6). As a result, both analogues remain 100% free and biologically active. While IGF-1 LR3 exhibits an extended half-life of 20–30 hours due to low clearance, Des(1-3)IGF-1 is cleared rapidly but displays a 10-fold higher affinity for the IGF-1R tyrosine kinase domain.
3. Cellular Signaling: PI3K/Akt/mTOR and Myogenesis
Binding to the alpha-subunits of IGF-1R induces trans-phosphorylation of the beta-subunit tyrosine kinase domains, recruiting insulin receptor substrate 1 (IRS-1). IRS-1 activates phosphoinositide 3-kinase (PI3K), leading to Akt/Protein Kinase B phosphorylation. Akt phosphorylates and inactivates GSK-3beta while activating mTORC1 (via Rheb-GTPase), driving ribosomal protein S6 kinase (p70S6K) phosphorylation and stimulating protein synthesis in C2C12 myoblast assays.
4. Reconstitution and Acetic Acid Buffer Protocol
Due to its complex tertiary structure stabilized by three intramolecular disulfide bonds, IGF-1 LR3 must be reconstituted in an acidic buffer (such as 10 mM to 100 mM sterile Acetic Acid or 0.1M HCl) before further dilution into PBS containing 0.1% BSA or sterile Bacteriostatic Water. Direct reconstitution into neutral water can cause peptide aggregation and irreversible precipitation.
5. Recombinant Protein Assay Controls & Aggregation Prevention
Unlike short linear peptides, folded proteins covered in IGF-1 LR3 vs Des(1-3)IGF-1 require orthogonal size-exclusion chromatography (SEC-HPLC) and reducing/non-reducing SDS-PAGE verification to confirm native monomeric structure (9117.5 g/mol). Prepare serial dilutions in low-binding polypropylene labware, avoid vortexing or air-liquid interface foaming, and store single-use aliquots to prevent freeze-thaw aggregation.
Peer-Reviewed References & Analytical Standards
- Francis G.L. et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology, 8(3), 213–223. [PMID: 1378283 ↗]
- Tomas F.M. et al. (1993). Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Biochemical Journal, 276(2), 547–554. [PMID: 2049080 ↗]
Referenced Laboratory Research Reagents
Batch-verified SwissLab catalog entries cited in this monograph
All analytical monographs and chemical data are published strictly for in-vitro laboratory research and scientific reference. Reagents must be handled by qualified personnel wearing appropriate PPE. Not for human or veterinary use.